Umbilical cord blood, collected within 15 minutes of birth, holds immense potential for treating various infant medical conditions. Processing involves RBC depletion, careful shipping, and cryopreservation—freezing within 24 hours of collection, allowing for indefinite storage.
Cord blood plays a vital role in pediatric medicine, particularly in treating childhood cancers, blood disorders like infant leukemia (juvenile chronic myelogenous leukemia and juvenile myelomonocytic leukemia), and immune system deficiencies. Chemotherapy, a common treatment, can harm healthy cells, making cord blood transfusions invaluable. Marrow transplants using cord blood introduce healthy blood cells, bolstering the infant’s immune system. Cord blood stem cells are also crucial in addressing rare genetic diseases, such as Krabbe Disease, a devastating condition causing mental and motor skill degeneration. Early stem cell intervention can preserve brain development. Other treatable disorders include Hurler Syndrome, Adrenoleukodystrophy, Metachromatic Leukodystrophy, Tay-Sachs disease, and Sandhoff disease. Hurler’s Syndrome, a progressive genetic disorder, stems from the body’s inability to produce a critical enzyme, damaging organs and leading to early mortality. Sandhoff disease causes progressive central nervous system deterioration, proving fatal before age three, similar to Krabbe Disease.
Cord blood offers more than just temporary relief; it provides a foundation for a new, healthy blood structure, strengthening the immune system and preventing future imbalances in affected infants.